简介：Objective:Ki-67playsanimportantfunctionincelldivision,butitsexactroleisstillunknown.Moreover,fewworksregardingitsoverallfunctionwerepublished.ThepresentstudyevaluatedtheclinicalsignificanceofKi-67indexasaprognosticmarkerandpredictorofrecurrenceindifferentmolecularsubtypesofbreastcancer.TherelationshipofKi-67indexwithdifferentclinicopathologicalfactorswasalsoanalyzed.Methods:Ki-67indexwasmeasuredin107casesofprimarybreastcancerfrom2010-2012.Thesepatientswereevaluatedforestrogenreceptor,progesteronereceptor,andHER2.Ki-67wasdividedaccordingtopercentagelevels:<15%and>15%.Followuprangedfrom32monthsupto6years.Results:Approximately44,23,15,and25casesweregroupedasluminalA,luminalB,HER2subtype,andtriple-negative(TN),respectively.NoluminalApatientsshowedKi-67levelhigherthan15%,andtheirrecurrencewas20%.InluminalBgroup,Ki-67levelhigherthan15%wasobservedin69%ofpatients,andrecurrencewas39%.InHER2subtype,Ki-67washigherthan15%in34%ofcases,andrecurrencewas40%.Intriple-negativecases,Ki-67washigherthan15%in60%ofcases,andrecurrencewasdetectedin32%ofpatients.PatientswithKi-67lessthan15%displayedbetteroverallsurvivalthanthosewithKi-67higherthan15%(P=0.01).PatientswithKi-67higherthan15%exhibitedhigherincidenceofmetastasisandrecurrencethanthosewithKi-67lessthan15%(P=0.000).Conclusions:Ki-67maybeconsideredasavaluablebiomarkerinbreastcancerpatients.

简介：流行性感冒A病毒(H1N1)，人的地方性的紧张的一个基因分类，鸟并且猪流感，穿过种类障碍到人并且显然获得了人的能力到人的传播。因为NS1蛋白质禁止抗病毒的干扰素/生产，H5N1子类型的一些紧张是高度剧毒的。另一蛋白质NS2调停到通过出口的细胞质的从原子核的病毒的ribonucleoprotein的出口信号。在这份报纸，我们学习了H1N1子类型的这些蛋白质的结构功能关系并且决定了他们的致病力的原因。我们的结果证明非保守的变化稍微稳定了或使动摇NS1或NS1-dsRNA建筑群的结构的域，稍微因此增加了或减少NS1蛋白质并且因而的函数提高了或减少H1N1病毒的致病力。不同紧张的NS2蛋白质在不同领域带了非保守的变化，导致功能的细微损失。这些变化稍微减少了病毒的致病力。因此，结果证实这些病毒的蛋白质的结构功能关系。

简介：瞄准：学习SSTR1，2，3，4，有在颜色的clinico病理学的因素，房间增长，Bcl-2和p53表示的5表示和他们的关系表面的癌症房间。方法：五种SSTR子类型，Ki-67，Bcl-2和p53染色的Immunohistochemical被标准streptavidin-peroxidase(SP)执行为127颜色的石蜡节的技术表面的癌症。并且在正常的40个标本的五种SSTR子类型的表示渲染表面的mucosae与一样的方法被检测。结果：为五种SSTR子类型的积极染色在颜色被观察表面的癌症房间和正常颜色表面的mucosae。SSTR1是最占优势的子类型在渲染表面的癌症，正常渲染表面的粘膜，并且第二是SSTR5或SSTR2。作为与正常相比渲染表面的粘膜，SSTR4更经常在颜色被表示表面的癌症房间(2.5%对18.9%，P<0.05)；SSTR2的表示，4，5在里面中等到很好区分的颜色，表面的腺癌在糟糕区分的(P<0.05)比那显著地高，在有积极淋巴节点转移的表面的癌症是的颜色的SSTR1表示比那显著地高与否定淋巴节点转移(72.2%和54.5%，P<0.05)。另外，颜色在溃疡的打表面的癌症，SSTR2表示显然被减少(P<0.05)；关联没到达在五SSTR子类型表情和Dukes'stages(P>0.05)之间的统计意义，但是SSTR1表示的频率与Dukes'stage增加，当SSTR3和SSTR5表示与公爵的阶段减少了时。而且，在象年龄那样的五种SSTR子类型和另外的clinicopathological因素的表示之间没有关联，性别，肿瘤地点，肿瘤深度，远转移。在肤色的增生的索引有SSTR2和SSTR3的否定表示的表面的癌症房间与积极表示(P<0.05)比那显著地高。在肤色的Bcl-2表示有SSTR1的积极表示的表面的癌症房间，2，3，5与否定表示(P<0.05)是比那显著地低的。在五种SSTR子类型和p53表示之间没有关联。结论：最占优势的SSTR子类型是SSTR1，并且第二是SSTR2或SSTR5。五�

简介：Objective:Therecurrenceorprogressionunderendocrinetherapyinhormonereceptor-positive(HR+)advancedbreastcancer(ABC)remainedacriticalclinicalchallenge.Chidamideisanoralsubtype-selectivehistonedeacetylase(HDAC)inhibitorwithmultiplefunctionsintumorgrowthinhibitionandmicroenvironmentmodulationviaepigeneticreprogramming.Thepurposeofthisstudywastoevaluatethesafety,pharmacokinetics(PK),andpreliminaryefficacyofchidamideincombinationwithexemestaneinHR+ABCpatients.Methods:EligiblepatientswerepostmenopausalwomenwithHR+ABCrecurrentorprogressedtoatleastoneendocrinetherapy.Bloodsampleswereobtainedintherun-inperiodandthefirstdayofcombinationtreatmentforPKanalysis.Incombinationtreatment,patientsweregivenexemestane25mgdailyandchidamide30mgtwiceaweek(BIW)untilprogressionofdiseaseorintolerabletoxicities.Atreatmentcyclewasdefinedas4weeks.Safety,PKparameters,andpreliminaryefficacywereevaluated.Results:Atotalof20patientswereenrolledbetweenJulyandDecember,2015.Themediannumberoftreatmentscyclewas5.2(20.8weeks)with2patientsstillontreatmentatthedatacut-offdateofOctober,2017.Thetreatment-relatedadverseevents(AE)≥grade3inmorethan2patientswereneutropenia(35%),thrombocytopenia(30%),andleucopenia(20%).Theplasmaexposureofexemestanewasconsistentinthepresenceorabsenceofchidamide.Aslightincreaseinchidamideexposurewasnotedinthepresenceofexemestane,probablyduetotheinter-andintra-patientvariations.Thebestresponsein16evaluablepatientswasassessedbyResponseEvaluationCriteriainSolidTumors(RECIST),including4patientswithpartialresponse,10patientswithstabledisease.Themedianprogression-freesurvival(PFS)was7.6months.Conclusions:ThecombinationofchidamidewithexemestanewasgenerallywelltoleratedwithpromisingpreliminaryefficacyinHR+ABCpatients.Theoverallresultsfromthisstudyencouragefurtherpivotaltrialinthispatie

简介：AbstractBackground:The development of carotid-cavernous fistulas (CCFs) during surgical recanalization of chronic internal carotid artery occlusion (ICAO) may be secondary to severe ICA dissection rather than a focal tear of the cavernous ICA seen in typical traumatic CCFs. The purpose of this study is to investigate the causal relationship between the CCFs and severe ICA dissections and to characterize technical outcomes after treatment with stenting.Methods:Five patients underwent treatment with self-expanding stents due to intraprocedural CCF and ICA dissection following surgical removal of ICAO plaque. The stents were telescopically placed via true channel of the dissection. Safety of the procedure was evaluated with 30-day stroke and death rate. Procedural success was determined by the efficacy of CCF obliteration and ICAO recanalization with angiography.Results:All CCFs were associated with spiral and long segmental dissection from the cervical to cavernous ICA. After stenting, successful dissection reconstruction with TICI 3 was achieved in all patients, with complete (n = 4) or partial CCF (n = 1) obliteration. No patient had CCF syndrome, stroke, or death during follow-up of 6 to 37 months; but one patient had pulsatile tinnitus, which resolved 1 year later. Angiography at 6 to 24 months demonstrated CCF obliteration in all 5 patients and durable ICA patency in 4 patients.Conclusions:Intraprocedural CCFs with spiral and cervical-to-cavernous ICA dissection during ICAO surgery are dissection-related because of successful obliteration after stenting for dissection reconstruction. Self-expanding stenting through true channel of the dissection, serving as implanting stent-autograft, may be an optimal therapy for the atypical CCF complication from ICAO surgery.